Supreme Court Restores Mifepristone Mail Access, Pausing 5th Circuit Restrictions
Updated
Updated · The New York Times · May 11
Supreme Court Restores Mifepristone Mail Access, Pausing 5th Circuit Restrictions
29 articles · Updated · The New York Times · May 11
A Supreme Court stay temporarily revived nationwide telemedicine prescribing and mail delivery of mifepristone after the Fifth Circuit had reinstated an in-person dispensing requirement.
Louisiana sued the FDA to block the 2021 mail-access policy, arguing the agency skipped adequate review and undermined the state’s abortion ban by letting residents obtain pills from elsewhere.
Medication abortion now accounts for about two-thirds of U.S. abortions, and more than one-fourth were provided via telemedicine in the first half of 2025, making the ruling immediately consequential.
Telehealth providers that had switched to misoprostol-only care resumed mifepristone prescribing, while one advance-provision service said requests jumped from 30-35 packages a month to 90-100 in the past week.
The Trump administration has stayed largely silent and skipped a Supreme Court brief, even as the FDA conducts a safety review that could shape the case and broader limits on courts directing drug policy.
If courts can overrule FDA science, could your everyday medications be challenged next?
As telehealth abortions surge, what happens to patients if the pill can no longer be mailed?
Can a state’s claimed financial harm be enough to block a nationwide medical policy?
Supreme Court Showdown: The Future of Mifepristone, FDA Authority, and Abortion Access in 2026
Overview
As of May 11, 2026, the future of mifepristone—a key abortion medication—hangs in the balance as legal battles intensify. Louisiana sued the FDA, arguing that the agency’s 2023 rule, which removed the in-person dispensing requirement for mifepristone, was illegal and led to more medication abortions even in states with strict bans. These challenges reflect broader efforts by some states to restrict abortion access by targeting federal regulations. The outcome of these disputes will shape how and whether patients and providers can access medication abortion, highlighting the high stakes for reproductive healthcare nationwide.